je.st
news
Tag: announces merck
Merck Announces Positive Study Investigating the Use of KEYTRUDA (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
2014-11-16 10:25:00| Merck.com - Research & Development News
Dateline City: ZURICH KEYTRUDA Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress ZURICH--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three week doses, respectively), compared to chemotherapy (P<0.0001 for both comparisons) Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Claire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
advanced
study
positive
Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Nave and Difficult-to-Cure Patients
2014-11-11 14:00:00| Merck.com - Research & Development News
Dateline City: BOSTON Final Results from the C-WORTHy Study (Parts A and B) Presented at The Liver Meeting and Published in The Lancet First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 2015 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742, the companys investigational NS3/4A protease inhibitor and NS5A inhibitor, respectively) with or without ribavirin (RBV) in treatment-nave and previously-treated (with peg-interferon/ribavirin [PR]) patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection -- the C-WORTHy study (Parts A and B). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
study
treatment
phase
Merck Offers Zilmax Progress Report; Announces New Label Approval
2014-11-05 22:11:00| Beef
By Joe Roybal Merck Animal Health provides a progress report on Zilmax safety studies, and announces a new FDA-approved label for component feeding of the beta agonist. read more
Tags: report
offers
progress
label
Merck Releases Zilmax Progress Report; Announces New Label Approval
2014-11-05 19:19:00| Beef
Merck Animal Health Merck Animal Health is announcing significant progress in the implementation of its Zilmax Five-Step Plan. With insights from the company’s advisory board, an extensive assessment and analysis of existing, as well as new, product data, was conducted. Additionally, Merck Animal Health obtained the input of industry experts, business partners and customers about the product and its use. read more
Tags: report
releases
progress
label
Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients
2014-11-03 11:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Phase 3 Clinical Trial Enrollment Scheduled to Start by the End of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection. Results were presented as a poster (#0434) and oral presentation by Dr. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCarmen de Gourville, 267-664-0146orInvestors:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
study
phase
patients
Sites : [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] next »